[go: up one dir, main page]

WO2002046750A3 - Methods of predicting chemotherapy response - Google Patents

Methods of predicting chemotherapy response Download PDF

Info

Publication number
WO2002046750A3
WO2002046750A3 PCT/US2001/051191 US0151191W WO0246750A3 WO 2002046750 A3 WO2002046750 A3 WO 2002046750A3 US 0151191 W US0151191 W US 0151191W WO 0246750 A3 WO0246750 A3 WO 0246750A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
predicting
patient
chemotherapy response
chemotherapy
Prior art date
Application number
PCT/US2001/051191
Other languages
French (fr)
Other versions
WO2002046750A2 (en
Inventor
Vladimir D Kravtsov
Mark J Koury
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Priority to AU2002239771A priority Critical patent/AU2002239771A1/en
Publication of WO2002046750A2 publication Critical patent/WO2002046750A2/en
Publication of WO2002046750A3 publication Critical patent/WO2002046750A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of predicting the effect of chemotherapy on a patient is disclosed. In this method, the patient is suffering from a disease or condition that can be treated or prevented by the administration to the patient of a drug which acts by inducing apoptosis. A method of predicting the effect of chemotherapy on the survival rate of a patient population suffering from a disease or condition that can be treated by chemotherapy is also disclosed.
PCT/US2001/051191 2000-11-13 2001-11-12 Methods of predicting chemotherapy response WO2002046750A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002239771A AU2002239771A1 (en) 2000-11-13 2001-11-12 Methods of predicting chemotherapy response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24705300P 2000-11-13 2000-11-13
US60/247,053 2000-11-13

Publications (2)

Publication Number Publication Date
WO2002046750A2 WO2002046750A2 (en) 2002-06-13
WO2002046750A3 true WO2002046750A3 (en) 2003-02-13

Family

ID=22933356

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/051191 WO2002046750A2 (en) 2000-11-13 2001-11-12 Methods of predicting chemotherapy response
PCT/US2001/051196 WO2002046751A2 (en) 2000-11-13 2001-11-13 Methods of predicting chemotherapy response

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051196 WO2002046751A2 (en) 2000-11-13 2001-11-13 Methods of predicting chemotherapy response

Country Status (2)

Country Link
AU (2) AU2002239771A1 (en)
WO (2) WO2002046750A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053704A1 (en) * 2003-12-01 2005-06-16 Novartis Ag Method for predicting drug responsiveness in myeloid neoplasms
WO2010135468A1 (en) * 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
BR112012024619A2 (en) * 2010-03-31 2016-05-31 Diatech Oncology Llc system and method for evaluating anticancer drug candidate
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
US6258553B1 (en) * 1996-11-14 2001-07-10 Vanderbilt University Assay for measuring apoptosis in cell culture

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAVTSOV V D ET AL: "Prediction of survival and responses to chemotherapy in acute myelogenous leukemia (AML) by the microculture kinetic (MiCK) assay of apoptosis.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 677A, XP001107076, ISSN: 0006-4971 *
KRAVTSOV VALDIMIR D ET AL: "Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.", BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 968 - 980, XP002118802, ISSN: 0006-4971 *
KRAVTSOV VLADIMIR D ET AL: "Chemotherapy of myeloid leukemia directed by a microculture kinetic (MiCK) assay for apoptosis.", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 724a, XP001106433, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2002046751A9 (en) 2002-12-27
WO2002046751A3 (en) 2004-01-08
WO2002046750A2 (en) 2002-06-13
AU2002241791A1 (en) 2002-06-18
WO2002046751A2 (en) 2002-06-13
AU2002239771A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
JP2004525194A5 (en)
WO2002003915A3 (en) Methods of producing weight loss and treatment of obesity
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2004071283A3 (en) Use of umbilical cord blood to treat individuals having a disease, disorder or condition
WO2005046603A3 (en) Pyridine compounds
WO2001098279A3 (en) Bis-arylsulfones
WO2005082382A8 (en) Formulations of thiomolybdate or thiotungstate compounds and uses thereof
WO2004066983A3 (en) Controlled release of highly soluble agents
TW200509896A (en) Analeptic and drug combinations
NO20054913L (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
WO2002046750A3 (en) Methods of predicting chemotherapy response
WO2004110364A3 (en) Thiotungstate analogues and uses thereof
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2005004806A3 (en) Combination therapy for treating chronic inflammatory diseases
HK1054324A1 (en) The treatment of inflammatory disorders
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
WO2002092064A3 (en) Therapeutic method for inducing tolerance
UA85187C2 (en) 2-aminobenzoyl derivatives
UA83017C2 (en) Combination of roflumilast and r.r-formoterol for treatment of respiratory tract disorders
WO2004075847A3 (en) METHODS AND COMPOUNDS FOR THE TREATMENT OF Aß­ ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS
AU6004300A (en) Treatment of angiogenesis dependent conditions with dextrin sulphate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP